| Description |
1 online resource (556 pages) : illustrations (color, black and white) |
| Contents |
Front cover -- Half title -- Full title -- Copyright -- Contents -- Contributors -- Foreword -- PART I -- Background -- CHAPTER 1 -- Legal classification and international systems for monitoring and responding to novel psychoactive substances -- Statement on the United Kingdom -- Key methodological points -- Introduction -- The origins of novel psychoactive substances -- Responding to novel psychoactive substances -- Legal classification of novel (new) psychoactive substances -- Terms and definitions -- International drug control system -- World health organization |
|
United nations office on drugs and crime -- National drug control laws -- Controls using consumer safety or medicines legislation -- Extending and adapting existing laws and processes -- Terms and definitions -- Developing new legislation to respond to novel substances -- European Union -- Joint action on new synthetic drugs 97/396/JHA, 1997-2005 -- Council Decision 2005/387/JHA, 2005-2018 -- Regulation (EU) 2017/2101 and Directive (EU) 2017/2103, 2018-onwards -- European Monitoring Center for Drugs and Drug Addiction -- Early warning, risk assessment, and control measures -- Early warning |
|
What substances are included within the scope of the eu early warning system? -- Early detection, reporting, assessment, and response -- Toxicovigilance -- Signal management -- Why is signal management important? -- How are signals managed? -- Monitoring open source information -- Risk communication -- Initial report -- Assessment of existing information -- Risk assessment -- Conceptual framework for risk assessment -- Control measures -- Current situation in Europe -- Overview of notifications -- Overview of seizures -- Opioids -- Case study: isotonitazene -- Synthetic cannabinoids |
|
Case study: MDMB-4en-PINACA -- Case study: 4F-MDMB-BICA -- Benzodiazepines -- Potential changes to the market in new benzodiazepines -- The future of novel psychoactive substances -- Global markets, glocal threats: the case for strengthened early warning, preparedness, and response measures -- COVID-19 pandemic -- Conclusion -- Acknowledgments -- References -- CHAPTER 2 -- Availability and supply of novel psychoactive substances -- Background -- Novel psychoactive substance market -- NPS origins and market entry -- NPS market structure -- Supply chain: manufacturing and distribution |
|
Sale of NPS -- Internet -- Retail vendors -- Street level drug dealers -- Products -- Pricing of NPS -- Transaction mechanisms -- Marketing -- Branding and packaging -- Misbranding -- Market dynamics -- Conclusions -- References -- CHAPTER 3 -- Prevalence of use of novel psychoactive substances -- Introduction -- General population surveys -- Surveys in young people -- Adult population surveys -- Examples of non-representative and convenience sample surveys -- Data from medical monitoring systems -- Alternative methodologies to assess use of NPS -- Summary and conclusions -- References -- CHAPTER 4 -- Pharmacological profiling of novel psychoactive substances |
| Bibliography |
Includes bibliographical references and index |
| Notes |
Description based upon print version of record |
| Subject |
Psychotropic drugs.
|
|
Psychotropic Drugs
|
|
Psychotropic drugs
|
| Form |
Electronic book
|
| Author |
Dargan, Paul I., editor
|
|
Wood, David M., editor
|
| ISBN |
9780128190302 |
|
0128190302 |
|
